Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
Showing 601–660 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
…temic sclerosis (SSc), improving overall survival compared with cyclophosphamide. However, 10–20% of patients relapse after AHSCT. Chimeric Anti…
…Merkt W, et al. Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associa…
…nfusion and the therapy was performed upon lymphodepletion with fludarabine (25 mg/m2 on days -5, -4, -3) and cyclophosphamide (1g/m2 on da…
…an difference -10.8, 95% CI -22.8 to 1.1; p = 0.07).Conclusions Cannabis oil demonstrated potential benefit in reducing joint pain in SSc pa…
…05±0.6;p=0.006], GI involvement [1.78±0.7;p=0.02], and those on bDMARD therapy [2.80±0.2; p=0.002]. A correlation was also found with …
… (r = 0.799, p < 0.001). Moderate correlations appeared between ScleroID lower GIT and UCLA constipation (r = 0.306, p = 0.031) and bloa…
…LR3 (19% vs 8%; p=0.03).Subsequent cancers were associated with cyclophosphamide (OR 2.6; CI 1.5-4.7), negatively with mycophenolate (OR 0.4; CI…
… with its inherent morbidity of diminished vision. She received Bevacizumab (an anti-angiogenic agent; an anti-VEGF-A agent) with which she…
…7.2% (Euroimmun) and 88.3% (AESKU) agreement with anti-PmScl-75/PmScl-100/Th-To in the line blot was found (k=0.448 and 0.494, respective…
… risk of developing the disease) which will be then followed by VEDOSS and/or definite SSc according to 2013 ACR/EULAR criteria. In th…
…RDs), immunosuppressive agents, vasodilators/antihypertensives, proton pump inhibitors, and other drugs used for the management of comorbidities. We o…
…8%, 11-cancer, 2- SSc), 7 Ca-ILD (53.9%, 3-cancer, 2-SSc), in 8 Ca-SSc (33.3%, 6-cancer, 1-SSc), in 22 SSc-ILD (28.9%, 20-SSc). Years …